跳至主要内容
临床试验/2024-516756-18-00
2024-516756-18-00招募中3 期

Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-modal approach.

Stichting Radboud universitair medisch centrum2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年6月30日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
20
试验地点
2
主要终点
The effect of atomoxetine vs. placebo on the percentage of time frozen during FOG-provoking gait tasks in the dopaminergic OFF-state.

研究概览

简要总结

To study the effect of atomoxetine FOG severity in the dopaminergic OFF-state.

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Male or female aged 18 years or older
  • Diagnosis of idiopathic Parkinson's disease according to Movement Disorders Society Diagnostic Criteria
  • Stabilised on optimal dopaminergic treatment for a minimum of four weeks prior to the baseline visit (Visit 1)
  • Presence of freezing of gait symptoms on a daily basis
  • Ability to walk for 10-meters unaided in the dopaminergic ON-state
  • Ability to provide written informed consent in accordance with ICH-GCP and local regulations
  • Willing and able to undergo all clinical trial assessments

排除标准

  • Current and/or previous (within 3 months) participation in a clinical trial
  • (History of) pheochromocytoma
  • Use of noradrenergic agents
  • Use of CYP2D6 inhibitors (SSRIs, quinidine, terbinafine)
  • Use of high dose salbutamol (or other beta2 agonists)
  • Pregnancy and/or breastfeeding
  • Known hypersensitivity to atomoxetine
  • Any contra-indications for undergoing MRI-scanning (e.g. claustrophobia or metal parts within the body such as DBS, an infusion pump or a pacemaker)
  • Co-morbidity that significantly impacts ambulation (e.g. orthopaedic or rheumatological ailments)
  • Severe cognitive impairment hampering the ability to comply with the study protocol
  • Active psychosis that would impact the ability to comply with the study protocol
  • Severe cardiovascular disorders: severe hypertension (Sustained (Sitting) hypertension of ≥180 mmHg systolic or ≥110 mmHg diastolic, defined by the average of three observations, each at least 3 minutes apart, with the participant having assumed the required position for at least 3 minutes), heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias, long QT interval syndrome (QTc > 500ms zettBa-formula) and channelopathies that would significantly compromise participant safety
  • Severe cerebrovascular disorders: cerebral aneurysm or recent/significant stroke
  • Hepatic or renal insufficiency
  • Narrow angle glaucoma

结局指标

主要结局

The effect of atomoxetine vs. placebo on the percentage of time frozen during FOG-provoking gait tasks in the dopaminergic OFF-state.

The effect of atomoxetine vs. placebo on the percentage of time frozen during FOG-provoking gait tasks in the dopaminergic OFF-state.

次要结局

  • The effect of atomoxetine vs. placebo on the percentage of time frozen during FOG-provoking gait tasks in the dopaminergic ON-state.
  • The effect of atomoxetine vs placebo on brain network topology, as calculated by the average integration/segregation coefficient.

研究者

发起方
Stichting Radboud universitair medisch centrum
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Franka Goossens

Scientific

Stichting Radboud universitair medisch centrum

研究点 (2)

Loading locations...

相似试验